Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome.

Abstract

Liver fibrosis is one of the common complications of transient myeloproliferative disorder (TMD) in Down syndrome (DS), but the exact molecular pathogenesis is largely unknown. We herein report a neonate of DS with liver fibrosis associated with TMD, in which we performed the serial profibrogenic cytokines analyses. We found the active monocyte chemoattractant protein-1 expression in the affected liver tissue and also found that both serum and urinary monocyte chemoattractant protein-1 concentrations are noninvasive biomarkers of liver fibrosis. We also showed a prospective of the future anticytokine therapy with herbal medicine for the liver fibrosis associated with TMD in DS.

DOI: 10.1097/MPH.0000000000000809

Cite this paper

@article{Kobayashi2017MonocyteCP, title={Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome.}, author={Kenichiro Kobayashi and Takako Yoshioka and Jun Miyauchi and Atsuko Nakazawa and Shigeaki Yamazaki and Hiromi Ono and Michiko Tatsuno and Kenta Iijima and Chiaki Takahashi and Yoko Okada and Kenji Teranishi and Takaaki Matsunaga and Chieko Matsushima and Mayo Inagaki and Minoru Suehiro and Saori Suehiro and Masahiko Nishitani and Hirohito Kubota and Jun Iio and Yoshinobu Nishida and Tetsuo Katayama and Narito Takada and Kentaro Watanabe and Tetsuro Yamamoto and Ryoji Yasumizu and Kentaro Matsuoka and Kentaro Ohki and Nobutaka Kiyokawa and Toshiro Maihara and Ikuya Usami}, journal={Journal of pediatric hematology/oncology}, year={2017}, volume={39 5}, pages={e285-e289} }